文献速递治疗药物监测与药物基因组学药物不良反应与药物警戒特殊人群用药

低白蛋白血症患者监测游离丙戊酸浓度的临床重要性

Clinical Importance of Monitoring Unbound Valproic Acid Concentration in Patients with Hypoalbuminemia.
PubMed 文献 · Pharmacotherapy · 2017-07-18

该回顾性研究纳入41例接受游离丙戊酸浓度检测的成人患者,分析低白蛋白血症时总浓度与游离浓度对神经系统不良反应的预测价值。结果显示总丙戊酸浓度与神经系统不良症状数相关性无统计学意义,而游离丙戊酸浓度与症状数显著相关,且预测至少一种神经系统不良症状的ROC曲线下面积更高。结论提示低白蛋白血症时需监测游离丙戊酸浓度。

要点

  • 低白蛋白血症时总丙戊酸浓度可能正常或偏低,但游离浓度已升高。
  • 游离丙戊酸浓度与神经系统不良症状数显著相关(r=0.384,p=0.013)。
  • 游离浓度预测神经系统不良症状的AUC为0.776(95%CI 0.629-0.923,p=0.007)。

核心结论

  • 低白蛋白血症时,尽管总丙戊酸浓度正常或偏低,游离丙戊酸浓度仍可能升高。
  • 高游离丙戊酸浓度与临床显著的神经系统不良症状相关。
  • 临床医生应意识到低白蛋白血症患者可能需要监测游离丙戊酸浓度。

研究设计与样本

  • 回顾性分析,纳入2008年1月1日至2015年4月30日在加拿大蒙特利尔一家大型学术三级医院接受游离丙戊酸浓度检测的41例成人患者(住院或门诊)。

主要发现

  • 多元线性回归中,总丙戊酸浓度(p<0.001)和白蛋白浓度(p<0.001)显著预测游离丙戊酸浓度。
  • 总丙戊酸浓度与神经系统不良症状数的相关系数为0.187(p=0.241),无统计学意义。
  • 游离丙戊酸浓度与神经系统不良症状数的相关系数为0.384(p=0.013),有统计学意义。
  • 总丙戊酸浓度预测至少一种神经系统不良症状的ROC曲线下面积为0.642(95%CI 0.449-0.836,p=0.167)。
  • 游离丙戊酸浓度预测至少一种神经系统不良症状的ROC曲线下面积为0.776(95%CI 0.629-0.923,p=0.007)。

临床怎么用

  • 对低白蛋白血症患者,若怀疑丙戊酸相关神经系统不良反应,应考虑监测游离丙戊酸浓度而非仅依赖总浓度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY OBJECTIVE: Because the pharmacokinetic evaluation of valproic acid (VPA) based on total drug concentration may be misleading in patients with hypoalbuminemia as a result of saturable protein binding and saturable metabolism, we sought to investigate the usefulness of therapeutic drug monitoring of unbound VPA concentration in a real-world clinical context, with a focus on clinically significant neurologic adverse outcomes. DESIGN: Retrospective analysis. SETTING: Large academic tertiary care hospital in Montreal, Canada. PATIENTS: Forty-one adults, hospitalized or followed as outpatients, for whom unbound VPA concentration testing was performed between January 1, 2008, and April 30, 2015. Patients were retrospectively identified by using the hospital's central laboratory database. MEASUREMENTS AND MAIN RESULTS: In the multiple linear regression analysis, the two variables that significantly predicted unbound VPA concentration were total VPA concentration (p<0.001) and albumin concentration (p<0.001). The correlation between total VPA concentration and the number of neurologic adverse symptoms was 0.187 (p=0.241), whereas the correlation between unbound VPA concentration and the number of neurologic adverse symptoms was 0.384 (p=0.013). The performance of total and unbound VPA concentrations in predicting the presence of at least one neurologic adverse symptom, as determined by the receiver operating characteristic curve, was 0.642 (95% confidence interval [CI] 0.449-0.836, p=0.167) and 0.776 (95% CI 0.629-0.923, p=0.007), respectively. CONCLUSION: This study showed that in the presence of hypoalbuminemia, high unbound VPA concentrations can be observed despite normal or low total VPA concentrations. It also demonstrated that high unbound VPA concentrations are associated with clinically significant neurologic adverse symptoms. Clinicians should be aware that unbound VPA concentration monitoring may be required in the presence of hypoalbuminemia.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Doré M, San Juan AE, Frenette AJ, et al. Clinical Importance of Monitoring Unbound Valproic Acid Concentration in Patients with Hypoalbuminemia. Pharmacotherapy. 2017. PMID: 28574586. doi:10.1002/phar.1965

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。